Inclusion Criteria:  Histology or cytology proven non-haematological cancer. At least one lesion in the bones is required. ECOG performance status ≤ 2. ≥ 18 years old. Life expectancy > 6 months. GTV diameter ≤ 5 cm. In case of de novo OMD and OMD recurrence a maximum of 5 targets (including the primary tumour) in a maximum of 3 organ sites are allowed. In case of OPD * and induced OMD*2 only 3 metastases (including the primary tumour) are allowed. The metastatic lesion(s) must be visible on a CT- or MR- scan and suitable for treatment with SABR. All metastatic sites are treated or planned for ablative therapy (including surgery) - for OPD only the sites in progression is required to fulfil this criterion. • A baseline scan within 28 days of inclusion (CT or PET- CT). For spine/paraspinal targets, an MR scan is mandatory, if epidural growth cannot be precluded on the baseline CT scan. No curative intended treatment option available. An ablative strategy should be deemed clinically relevant and is at the discretion of the treating physician to decide. Ability to understand and the willingness to sign a written informed consent document.  Exclusion Criteria:  Patient cannot tolerate physical set up required for SABR. Uncontrolled intercurrent illness. Pregnancy. Bilsky score ≥ 1b. If the patient is treated with surgery, a pre-operative Bilsky score ≥ 1b is an exclusion criterion as well. See appendix A for Bilsky score. Presence of myelopathy from the target area. Candidate for surgical treatment (determined by the institutions clinical oncologist, neurosurgeon or orthopaedic surgeon). For spine/paraspinal lesions where epidural growth cannot be precluded on the baseline CT scan: patients for whom an MR scan is contraindicated. Mechanical instability and/or fracture risk *3. For spine disease, involvement of ≥ three contiguous vertebrae. Uncontrolled disease in respect to malignant pleural effusion, ascites, lymphangitic carcinomatosis, pleural carcinomatosis or peritoneal carcinomatosis. Patients with uncontrolled brain metastases. If the patient has received previous radiotherapy, the combined dose at the radiation site must not exceed the dose constraints according to Appendix B. -